BMX (Bone Marrow Tyrosine Kinase on chromosome X), also known as ETK, is a non-receptor tyrosine kinase belonging to the TEC kinase family. It plays a critical role in intracellular signaling, particularly in pathways regulating cell survival, proliferation, and differentiation. BMX is predominantly expressed in cells of hematopoietic origin, endothelial cells, and certain epithelial tissues. It interacts with key signaling cascades, including PI3K/AKT, STAT, and NF-κB, often activated by cytokine receptors or integrins. Dysregulation of BMX has been implicated in cancer progression, immune disorders, and angiogenesis, making it a potential therapeutic target.
BMX antibodies are essential tools for studying its expression, activation, and functional roles. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to detect BMX levels in tissues or cell lines. Specific antibodies targeting phosphorylated BMX (e.g., at Tyr40) help assess its kinase activity in pathological conditions. Research utilizing BMX antibodies has shed light on its involvement in drug resistance, tumor microenvironment modulation, and inflammatory diseases. Recent studies also explore BMX inhibition as a strategy to counteract oncogenic signaling, highlighting its translational relevance in precision medicine.